Lv1
80 积分 2023-03-21 加入
The landscape for radioligand therapies in oncology
1天前
求助中
An innovative antibody fusion protein targeting PD-L1, VEGF and TGF-β with enhanced antitumor efficacies
17天前
已完结
Engineering of Fc1 and Fc3 from human immunoglobulin G to analyse subclass specificity for staphylococcal protein A
2个月前
已完结
A tool for analyzing complex epitope binning data of monoclonal antibodies
6个月前
已完结
The Journey of Antibody–Drug Conjugates: Lessons Learned from 40 Years of Development
7个月前
已完结
Recent advances and impending challenges for the radiopharmaceutical sciences in oncology
7个月前
已完结
Living in LALA land? Forty years of attenuating Fc effector functions
9个月前
已完结
Living in LALA land? Forty years of attenuating Fc effector functions
9个月前
已完结
Cergutuzumab amunaleukin (CEA-IL2v), a CEA-targeted IL-2 variant-based immunocytokine for combination cancer immunotherapy: Overcoming limitations of aldesleukin and conventional IL-2-based immunocytokines
11个月前
已完结
皖公网安备34019202002308
